BATE KENNETH

SEC Form 4 insider trading activity

BATE KENNETH has filed 2 SEC Form 4 filings (21 transaction rows) across 1 company, with disclosures dating back to 2025. 1 of those filings fall inside the rolling window. Most recent filing: Nov 7, 2025.

On the most recent filing, BATE KENNETH is listed as Director at MADRIGAL PHARMACEUTICALS, INC. Inside the rolling window, BATE KENNETH reported no open-market purchases and 1 open-market sale totaling $8.0M in MDGL.

Companies traded

Other insiders at MDGL

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$8.0M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
MDGL
BATE KENNETH
Sale$8.0MNov 7SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has BATE KENNETH made?

BATE KENNETH has filed 2 SEC Form 4 filings (21 transaction rows) across 1 company since 2025.

Which companies does BATE KENNETH trade?

BATE KENNETH has filed SEC Form 4 disclosures for 1 company, including MDGL.

When was BATE KENNETH's most recent SEC Form 4 filing?

BATE KENNETH's most recent SEC Form 4 filing on Tracefour is dated Nov 7, 2025.

What is BATE KENNETH's total buy and sell value in the current window?

Inside the rolling retention window, BATE KENNETH bought $0 and sold $8.0M based on SEC Form 4 filings.

What was BATE KENNETH's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 16,575 MDGL shares on 2025-11-05, worth $8.0M, per SEC Form 4 filings.